指南与共识肾癌与肾肿瘤

2021年EAU肾细胞癌指南更新:ICI联合方案成为晚期透明细胞肾癌一线标准

The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
指南 / 共识 · Eur Urol · 2021-05-29

该指南基于CLEAR、CheckMate-9ER、Keynote-426和CheckMate-214等随机III期试验结果更新推荐。对于初治转移性透明细胞肾细胞癌,推荐三种TKI联合ICI方案用于所有IMDC风险组,双免疫联合用于中高危组。

要点

  • TKI联合ICI(阿昔替尼+帕博利珠单抗、卡博替尼+纳武利尤单抗、仑伐替尼+帕博利珠单抗)为所有IMDC风险组一线推荐。
  • 伊匹木单抗+纳武利尤单抗仅推荐用于IMDC中危和低危组。
  • CLEAR试验显示仑伐替尼+帕博利珠单抗较舒尼替尼改善PFS、OS和ORR。

核心结论

  • 基于ICI的联合疗法是初治转移性透明细胞肾细胞癌的标准治疗。

研究设计与样本

  • 欧洲泌尿外科学会(EAU)肾细胞癌指南小组基于多项随机对照III期试验结果制定推荐。

主要发现

  • CLEAR试验显示仑伐替尼+帕博利珠单抗较舒尼替尼改善PFS、OS和ORR。
  • CheckMate-9ER更新显示卡博替尼+纳武利尤单抗较舒尼替尼持续改善PFS、OS和生活质量。
  • Keynote-426更新显示阿昔替尼+帕博利珠单抗在意向治疗人群中改善PFS,且在所有IMDC亚组中均见PFS获益。
  • CheckMate-214试验在中危和低危组中证实伊匹木单抗+纳武利尤单抗的OS获益,PFS在30个月后趋于平台。

关键数值与推荐

  • 推荐阿昔替尼+帕博利珠单抗、卡博替尼+纳武利尤单抗、仑伐替尼+帕博利珠单抗三种TKI+ICI联合方案用于晚期一线肾细胞癌的所有IMDC风险组。
  • 推荐伊匹木单抗+纳武利尤单抗双免疫联合用于IMDC中危和低危组。

临床怎么用

  • 初治转移性透明细胞肾细胞癌应优先选择基于ICI的联合方案,根据IMDC风险分层选择TKI+ICI或双免疫治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The recent randomized controlled phase III CLEAR trial results are the last to complement immune checkpoint inhibitor (ICI)-based doublet combination therapies for treatment-naïve metastatic clear-cell renal cell carcinoma. The CLEAR trial demonstrated an improved progression-free survival (PFS), overall survival (OS), and an objective response rate (ORR) benefit for the combination of lenvatinib plus pembrolizumab over sunitinib. The CheckMate-9ER trial update demonstrated an ongoing PFS, OS, and quality-of-life benefit for cabozantinib plus nivolumab over sunitinib as did the update of Keynote-426 for axitinib plus pembrolizumab in the intention-to-treat population, with a PFS benefit seen across all International Metastatic Database Consortium (IMDC) subgroups. In the IMDC intermediate- and poor-risk groups, the CheckMate-214 trial of ipilimumab plus nivolumab confirmed the OS benefit with a PFS plateauing after 30 months. The RCC Guidelines Panel recommends three tyrosine kinase inhibitors + ICI combinations of axitinib plus pembrolizumab, cabozantinib plus nivolumab, and lenvatinib plus pembrolizumab across all IMDC risk groups in advanced first-line RCC, and dual immunotherapy of ipilimumab and nivolumab in IMDC intermediate- and poor-risk groups. PATIENT SUMMARY: New data from combination trials with immune checkpoint inhibitors for advanced kidney cancer confirm a survival benefit for lenvatinib plus pembrolizumab, cabozantinib plus nivolumab (with improved quality-of-life), axitinib plus pembrolizumab, and ipilimumab plus nivolumab. These combination therapies are recommended as first-line treatment for advanced kidney cancer.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Bedke J, Albiges L, Capitanio U, et al. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care. Eur Urol. 2021. PMID: 34074559. doi:10.1016/j.eururo.2021.04.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。